无码AV天堂一区二区三区_免费观看又色又爽又黄的崩锅_夜夜春夜夜爽_亚洲aⅴ无码成人网站国产_日本老熟妇乱子伦视频_男女啪啪高潮激烈免费版_国产狂喷潮在线观看_国产成人一区二区三区免费视频_性色av无码专区一ⅴa亚洲_

T-Cell Involver T-Cell Engager (TCE) Multifunctional T-Cell Engager (mTCE)
T-Cell Involver
Program Target Indication Mono/Combo preclinical IND-Enabling Phase 1 phase 2 Rights
DNV3 LAG-3 Solid Tumors Mono Global
Malignant Melanoma +Toripalimab*+ Chemo*
  • Mechanism of Action: Anti-LAG-3 monoclonal antibody
    Indication: Solid tumors
    Development Plan: Clinical trial ongoing in China
    Preclinical Highlights: Strong immune activation in xenogeneic models
    Partnering Status: Open to co-development / licensing
T-Cell Engager (TCE)
Program Platform Target Indication Mono/Combo Preclinical IND-Enabling Phase 1 phase 2 Rights
SMET12 H-BiTE? EGFR × CD3 Solid Tumors Mono Global
Solid Tumors +Toripalimab*
CMD011 H-BiTE? GPC3 × CD3 Hepatocellular Carcinoma Mono Global
CMDE005 Pro-BiTE? EGFR × CD3 Solid Tumors Mono Global
Undisclosed Pro-BiTE? Undisclosed Solid Tumors Mono Global
  • Mechanism of Action: H-BiTE? with EGFR × CD3
    Indication: Solid tumors
    Development Plan: Clinical trial ongoing in China; US IND cleared by FDA
    Preclinical Highlights: Excellent manufacturability and stability
    Partnering Status: Open to co-development / licensing
  • CMD011 - Project Detail
    Mechanism of Action: Hepatocellular Carcinoma (HCC)
    Indication: Solid tumors
    Development Plan: Clinical trial ongoing in China; US IND cleared by FDA
    Preclinical Highlights: Strong and selective binding to GPC3+ tumor cells with minimal off-target reactivity
    Partnering Status: Open to co-development / licensing
  • CMDE005 - Project Detail
    Mechanism of Action: Pro-BiTE? with EGFR × CD3
    Indication: Solid tumors
    Development Plan: Clinical trial ongoing in China; US IND cleared by FDA
    Preclinical Highlights: Inactive in normal tissue environments, selectively activated in TME by tumor-expressed enzymes
    Partnering Status: Open to co-development / licensing
  • Undisclosed
Multifunctional T-Cell Engager (mTCE)
Program Platform Target Indication Mono/Combo preclinical IND-Enabling Phase 1 phase 2 Rights
Undisclosed Tri-Specific Antibody Undisclosed Undisclosed Mono Global
  • Undisclosed
* Toripalimab and Chemo are Externally Soruced and Not Proprietary
Single-Nation Development in China
Global Development
  • Mono = Monotherapy
  • Combo = Combination Therapy
  • IND = Investigational New Drug